Eli Lilly’s anticipation for the Food and Drug Administration’s approval decision regarding its Alzheimer’s treatment, donanemab, faces a setback as the agency extends its review timeline. In a surprising move, the FDA intends to convene an impromptu meeting with external advisors to delve deeper into the drug’s safety and efficacy, prompting uncertainties around the approval date.
Initially slated for approval by the end of the first quarter, the FDA’s decision deadline was already postponed from its expected approval last year. Eli Lilly’s donanemab showed promising results in significantly slowing Alzheimer’s progression in late-stage trials, although concerns linger over safety issues like brain swelling and bleeding associated with similar drugs.
The delay underscores the FDA’s cautious approach in evaluating Alzheimer’s treatments, given the condition’s pervasive impact and the urgent need for effective therapies. Eli Lilly remains optimistic about donanemab’s potential to offer substantial benefits to those with early symptomatic Alzheimer’s, despite the unexpected regulatory hurdle.
The FDA’s forthcoming review will scrutinize an 18-month phase three trial involving over 1,700 patients in the early stages of Alzheimer’s, focusing on safety outcomes and the trial’s unique design. Eli Lilly’s commitment to working closely with the FDA and stakeholders underscores its dedication to navigating the regulatory process and addressing concerns surrounding donanemab’s development.
You might like this article:U.S. Labor Market Resilience Shows in February Job Data
